Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.19.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2019
Segment Reporting [Abstract]  
Summary of Segment Information
The following table summarizes segment information for the three month periods ended March 31, 2019 and 2018, respectively (in thousands).    
Three Months Ended March 31,
2019 2018
Net revenues:
Clinical Services $ 86,210  $ 56,971 
Pharma Services 9,367  6,452 
Total Revenue $ 95,577  $ 63,423 
Cost of revenue:
Clinical Services $ 42,651  $ 31,042 
Pharma Services 5,811  5,078 
Total Cost of Revenue $ 48,462  $ 36,120 
Gross Profit:
Clinical Services $ 43,559  $ 25,929 
Pharma Services 3,556  1,374 
Total Gross Profit $ 47,115  $ 27,303 
Operating expenses:
General and administrative $ 32,142  $ 17,067 
Research and development 1,209  956 
Sales and marketing 11,216  6,775 
Total operating expenses 44,567  24,798 
Income from Operations 2,548  2,505 
Interest expense, net 1,826  1,486 
Other expense (income) 5,169  (63)
(Loss) income before taxes (4,447) 1,082 
Income tax (benefit) expense (2,023) 438 
Net (Loss) Income $ (2,424) $ 644